SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001694665-23-000128
Filing Date
2023-07-20
Accepted
2023-07-20 16:21:06
Documents
16
Period of Report
2023-07-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K evlo-20230714.htm   iXBRL 8-K 28746
2 EX-10.1 exhibit101leasetermination.htm EX-10.1 42519
6 evlo-20230714_g1.jpg GRAPHIC 7885
7 image_0a.jpg GRAPHIC 5731
8 image_1a.jpg GRAPHIC 6863
  Complete submission text file 0001694665-23-000128.txt   248556

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evlo-20230714.xsd EX-101.SCH 1905
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evlo-20230714_lab.xml EX-101.LAB 24833
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evlo-20230714_pre.xml EX-101.PRE 13049
10 EXTRACTED XBRL INSTANCE DOCUMENT evlo-20230714_htm.xml XML 2814
Mailing Address 620 MEMORIAL DRIVE SUITE 500 CAMBRIDGE MA 02139
Business Address 620 MEMORIAL DRIVE SUITE 500 CAMBRIDGE MA 02139 617-577-0300
Evelo Biosciences, Inc. (Filer) CIK: 0001694665 (see all company filings)

IRS No.: 465594527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38473 | Film No.: 231100087
SIC: 2834 Pharmaceutical Preparations